Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P452

Usability study of a smartphone-based patient monitoring system measuring Calprotectin for therapy follow-up

Authors:

C. Reinhard*1, J. Weber2, C. Niederberger1, F. Perretta3

1BÜHLMANN Laboratories AG, Operations, Schoenenbuch, Switzerland, 2BÜHLMANN Laboratories AG, R&D, Schoenenbuch, Switzerland, 3BÜHLMANN Laboratories AG, QA, Schoenenbuch, Switzerland

P453.

Incidence of side effects and unspecific infections in the therapy with immunosuppressive therapeutics: a prospective observational study in 158 IBD patients

Authors:

S. Mair, Y. Atabay, K. Mayer, A. Petersen, R.M. Schmid, W. Huber, Technical University Munich, II. Medical Department, Munich, Germany

P453. ABCB1 and CHDH polymorphisms predict early Crohn's disease onset: Results from a fine mapping of one-carbon metabolism pathway genes
P453. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset ulcerative colitis
Authors:

T. Yamamoto1, M. Shiraki1, S. Umegae1, K. Matsumoto1, 1Yokkaichi Social Insurance Hospital, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P453

Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease (IBD): Patient factors influencing infliximab pharmacokinetics

Authors:

J. Guardiola*1, L. Rodriguez-Alonso1, E. Santacana2, N. Padullés2, H. Colom3, A. Padullés2, C. Arajol1, A. Ruiz-Cerulla1, S. Cobo2, J. Bas4, J. Climent4, F. Morandeira4, F. Rodriguez-Moranta1

1Hospital Universitario de Bellvitge, Gastroenterology, L´Hospitalet de Llobregat, Spain, 2Hospital Universitario de Bellvitge, Pharmacy, L´Hospitalet de Llobregat, Spain, 3Barcelona University, Pharmacokinetics. School of Pharmacy, Barcelona, Spain, 4Hospital Universitario de Bellvitge, Immunology, L´Hospitalet de Llobregat, Spain

P454.

In IBD outpatients knowledge of fecal calprotectin and infliximab trough levels significantly enhances infliximab dose escalation decision making

Authors:

V.W. Huang, C. Prosser, C. Shalapay, D.K. Fedorak, N. Dhami, H. Wang, K.I. Kroeker, R.N. Fedorak, University of Alberta, Medicine, Edmonton, Canada

P454. A novel methylation panel for the early detection of neoplasia in high risk ulcerative colitis and Crohn's colitis patients
P454. Leucocytosis due to azathioprine in a patient with Crohn's disease
Authors:

D.G. Duman1, E. Bicakci1, 1Saglik Bakanligi Marmara Universitesi EAH, Gastroenterology, Istanbul, Turkey

P454

A protocol to avoid corticosteroids in Crohn's disease requiring luminal surgery

Authors:

K.V. Patel*1, C.I. Amadi1, D.V. O'Hanlon2, S. Fong1, I. Nasr1, E. Westcott3, A.B. Williams3, A.A. Darakhshan3, J.D. Dunn1, P.M. Irving1, S.H. Anderson1, J.D. Sanderson1

1Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Guy's and St Thomas' NHS Foundation Trust, Dietetics, London, United Kingdom, 3Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, United Kingdom

P455.

Improvement of ulcerative-colitis-associated microbiota dysbiosis after treatment with mesalazine-MMX (Mezavant®) using mucosal Faecalobacterium prausnitzii/Escherichia coli index as a marker

Authors:

J.O. Miquel Cusachs1, D. Busquets Casals2, M. Serra-Pages1,3, J. Garcia-Gil4, X. Aldeguer Manté1, 1Hospital universitari de Girona, Dr Trueta, Gastroenterology, Girona, Spain, 2Hospital Universitari de Girona, Gastroenterology. IBD unit, Girona, Spain, 3IDiBGi, Gastroenterology. IBD unit, Girona, Spain, 4Universitat de Girona, Biology, Girona, Spain

P455. Lessons learnt from the design and implementation of a web-based intervention to support self-management in inflammatory bowel disease (IBD)
Authors:

C. Calvert1, S. Lal2, C. Stansfield2, J. McLaughlin1, A. Robinson2, 1Manchester University, School of Translational Medicine, Manchester, United Kingdom, 2Salford Royal Foundation Trust, Gastroenterology, Salford, United Kingdom

P455. Westernalised diet on CEABAC10 mice induces a specific dysbiosis with increased Escherichia coli and favours AIEC colonization promoting inflammation
P455

Need and predictors of colectomy for Ulcerative Colitis patients in the biologic therapy era. A real life experience in a tertiary referral center

Authors:

N. Viazis*, J. Anastasiou, M. Giakoumis, M. Chanias, X. Tzannetakou, I. Internos, A. Tsigaridas, E. Anastasopoulos, D. Karamanolis

Evangelismos Hospital, Gastroenterology Department, Athens, Greece

P456.

Impact of short-term and long-term daily therapy with MMX mesalazine on work-related outcomes in patients with mild-to-moderate ulcerative colitis

Authors:

A. Yarlas1, M.K. Willian2, A.V. Joshi2, 1Optum, Life Sciences, Lincoln, RI, United States, 2Shire, Health Economics and Outcomes Research, Wayne, PA, United States

P456. Cell detachment and diffuse adherent Escherichia coli pathotypes, frequently occured in our IBD patients and their ability to induce proinflammatory response
P456. Late perianal fistulas after IPAA
Authors:

T. Emmanouil1, S. Gavriel2, A. Tachtaras3, N. Giannoulakos3, V. Maniatis3, S. Baratsis2, 1Iaso General, Gastroenterology, Athens, Greece, 2Iaso General, Surgery, Athens, Greece, 3Iaso General, Radiology, Athens, Greece

P456

First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population.

Authors:

D. Jarzebicka*1, A. Plocek2, J. Sieczkowska1, E. Toporowska-Kowalska2, J. Kierkus1

1The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland, 2Medical University of Łódź, Department of Paediatric Allergology, Gastroenterology and Nutrition, Łódź, Poland

P457.

Impact of medical therapies on the natural history in ulcerative colitis. An 8-year follow-up of a cohort study from a tertiary center

Authors:

A. Indriolo, P. Ravelli, Papa Giovanni XXIII Hospital, Gastroenterology and Digestive Endoscopy Unit, Bergamo, Italy

P457. Activation of intestinal epithelial autophagy as a potential and novel mechanism of probiotic action in the gut
P457. Laparoscopic approach for inflammatory bowel disease is a real alternative to open surgery: an experience in 422 consecutive patients
Authors:

L. Maggiori1, A. Khayat1, X. Tréton2, F. Bretagnol1, Y. Bouhnik2, Y. Panis1, 1Hôpital Beaujon, Colorectal surgery, Clichy, France, 2Hôpital Beaujon, Gastroenterology & Nutritive Assistance, Clichy, France